Tremfya Market: Role of Biologic Therapies and Expanding Indications
The Tremfya market was valued at USD 4.2 billion in 2025 and is projected to reach USD 7.99 billion by 2034, growing at a CAGR of 7.40% from 2026 to 2034, according to Polaris Market Research. Several factors support this growth: a rising preference for biologic therapies over traditional systemic treatments, higher healthcare spending, and better access to specialty medicines. Tremfya (guselkumab), made by Johnson & Johnson, is used for inflammatory skin, joint and bowel conditions, which gives it a broad patient base across several therapeutic areas.
Understanding Tremfya
Tremfya is a biologic monoclonal antibody that blocks interleukin-23 (IL-23), a protein involved in the inflammation behind several autoimmune diseases. It is given by subcutaneous injection, and after initial loading doses the maintenance schedule is typically every eight weeks. Traditional treatments such as topicals, phototherapy and broad immunosuppressants often need more frequent dosing and adjustment. Tremfya’s targeted action and less frequent dosing make it attractive for long-term disease control. The drug is approved for moderate-to-severe plaque psoriasis, active psoriatic arthritis, ulcerative colitis and Crohn’s disease. As a result, the Tremfya market now spans dermatology, rheumatology and gastroenterology.
Rising Disease Prevalence Fuels Demand
The main growth driver is the increasing number of people diagnosed with chronic plaque psoriasis and psoriatic arthritis. These long-term autoimmune conditions need ongoing treatment, and better awareness and diagnosis rates are expanding the pool of eligible patients. A 2024 study in Acta Dermato-Venereologica found that psoriatic arthritis among psoriasis patients in Korea rose from 6.17 per 1,000 patients in 2008 to 19.03 per 1,000 in 2020. The National Psoriasis Foundation estimates that 2% to 3% of the global population is affected by psoriasis. A patient pool that large keeps demand for advanced biologics steady.
Clinical Evidence and Expanding Indications
Clinical results and label expansions also strengthen the Tremfya market. The FDA approved guselkumab for ulcerative colitis in September 2024 and for Crohn’s disease in March 2025. Data from the Phase 3b APEX study, announced in June 2025, showed that it significantly slowed joint structural damage in active psoriatic arthritis. A May 2026 FDA label expansion backed this finding, making Tremfya the only IL-23 inhibitor proven to slow structural joint damage progression in adults with active psoriatic arthritis. Each new indication widens the patient base and builds prescriber confidence.
Segment Highlights
By application, plaque psoriasis held the largest share at 85.31% in 2025, reflecting how common the condition is and how well Tremfya clears skin lesions. Psoriatic arthritis is expected to grow fastest, as awareness rises and evidence builds that the drug addresses both joint and skin symptoms.
By distribution channel, hospital pharmacies led with a 51.52% share in 2025. Biologics need specialized handling, storage and administration, and hospitals house the specialists who prescribe them. Online pharmacies are expected to grow fastest, helped by home delivery, telehealth and improving cold-chain logistics.
Explore The Complete Comprehensive Report Here : https://www.polarismarketresearch.com/industry-analysis/tremfya-market
Regional Perspective
North America dominated in 2025 with a 41.22% share. It benefits from advanced healthcare infrastructure, high biologic adoption and large healthcare spending. The U.S. accounted for 83.12% of the regional market, supported by strong awareness among dermatologists and rheumatologists and access to patient assistance programs.
Europe is a substantial and growing market. EMA approvals across indications, including Crohn’s disease in May 2025, support wider availability, and Germany stands out for its reimbursement policies and early adoption of new therapies.
Asia Pacific is expected to record the highest regional CAGR of 10.8%. Urbanization, better diagnostics and government investment in healthcare infrastructure are driving demand, with Japan a prominent contributor.
Competition, Pipeline and Access
Johnson & Johnson leads the Tremfya market through its immunology experience, label expansion strategy and physician education efforts. Competing therapies include other IL-23 inhibitors, IL-17 inhibitors, TNF-alpha inhibitors and small-molecule options such as PDE4 and JAK inhibitors. Companies including Bio-Thera Solutions, Alvotech and Samsung Bioepis are working on IL-23 inhibitor biosimilars ahead of patent expiry. J&J is also advancing an oral IL-23 receptor antagonist, JNJ-2113, and the TYK2/JAK1 inhibitor TLL-018 to complement its immunology portfolio.
Cost remains a barrier. Biologics are expensive, and insurance coverage varies by payer and region. Programs such as Janssen CarePath and the Johnson & Johnson Patient Assistance Foundation offer copay support and, for eligible uninsured patients, free access to the drug. High entry barriers, including cold-chain logistics, specialized manufacturing and strict regulatory requirements, limit new competitors.
Tremfya market growth over the coming decade will depend on how well Johnson & Johnson balances label expansion, patient access and pipeline innovation against biosimilar pressure and pricing scrutiny. With strong clinical evidence, a widening range of approved conditions and rising demand in emerging regions, the outlook is positive. Stakeholders who invest in research, support patient affordability and widen distribution, including online channels, are best placed to benefit as targeted biologic therapies become central to autoimmune care.
More Trending Latest Reports By Polaris Market Research:
Computer Numerical Control Machine Market
Specialty Food Ingredients Market
3D Microfluidic Cell Culture Market
Specialty Food Ingredients Market
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Games
- Gardening
- Health
- Home
- Literature
- Music
- Networking
- Other
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness